(Regeneron) Regeneron Pharmaceuticals Inc. has announced that a single dose of its antibody cocktail, REGEN-COV, minimized the risk of contracting Covid-19 by 81.6%.
The efficacy results came from a late-stage study and were produced two to eight months after the administration of the antibody therapy.
In the eight-month assessment period, there were no reported hospitalizations in the REGEN-COV group, compared to six in the placebo group. No deaths or safety signals were reported during the assessment period for individuals under REGEN-COV.
Within one month of administration, REGEN-COV reduced Covid-infection risk by 81.4%.
The results are a positive development for individuals with compromised immune systems and those with poor response to the vaccines.
REGN: NASDAQ is up +1.79% on premarket.
